Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Studies on the prevalence of wheezing in both the asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) and non-ACO groups, as well as the clinical characteristics of wheezing patients in each group, are rare. We examined the prevalence of wheezing in ACO patients and non-ACO patients, respectively. In addition, we aimed to determine clinical characteristics of patients with wheezing compared to those without wheezing in the ACO and non-ACO groups.
Methods: We analyzed the data from the Korean COPD Subgroup Study (KOCOSS), a multicenter prospective cohort. We classified patients into four groups according to whether they were ACO patients or had self-reported wheezing based on the patient's answer to the COPD-specific version of St. George's Respiratory Questionnaire (SGRQ-C): ACO with wheezing, ACO without wheezing, non-ACO with wheezing, and non-ACO without wheezing. Clinical characteristics and exacerbations during 1-year follow up were compared among four groups.
Results: Wheezing was present in about 56% of patients in the ACO and non-ACO groups. In both groups, patients with wheezing exhibited more severe symptoms, worse lung function, and a higher risk of exacerbation than those without wheezing. There was no association between blood eosinophil count and wheezing in both the ACO and non-ACO groups. During 1-year follow-up, the ACO with wheezing group experienced exacerbations the most frequently, followed by the non-ACO with wheezing group. Moreover, wheezing was an independent predictor of the risk of exacerbation in patients with COPD, irrespective of both the ACO phenotype and the severity of airflow limitation. The exacerbation risk was higher in COPD patients who experienced wheezing more frequently.
Conclusions: Wheezing, reflecting more prominent airflow limitation and predicting exacerbation development, may serve as a severe phenotype of COPD rather than being indicative of an ACO phenotype.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713320 | PMC |
| http://dx.doi.org/10.21037/jtd-23-1031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early preschool wheeze trajectories are predominantly non-allergic with distinct biologic and microbiome traits.
J Allergy Clin Immunol
September 2025
Department of Pediatrics, and Translational Medicine, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address:
Background: Disentangling preschool wheezing heterogeneity in terms of clinical traits, temporal patterns, and collective healthcare burden is critical for precise and effective interventions.
Objective: We aimed to collectively define contributions and distinct characteristics of respiratory phenotypes based on longitudinal wheeze and atopic sensitization patterns in the first 5 years of life.
Methods: Group-based trajectory analysis was performed in the CHILD Cohort study to identify distinct wheeze and allergic sensitization trajectories.
New Asthma Diagnosis Codes or Short-Acting β Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018-2023.
Mycoses
September 2025
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Background: Although several fungal infections have been linked to asthma development, the relationship between histoplasmosis and asthma development has not been fully described.
Objectives: To assess the incidence of new asthma diagnosis codes or short-acting β agonist (SABA) prescription in the year following histoplasmosis diagnosis and identify potentially related factors.
Methods: We used a large health insurance claims database to identify patients with histoplasmosis with and without an asthma diagnosis code or a short-acting β agonist prescription in the year after diagnosis.
Beyond respiratory syncytial virus and rhinovirus: The other viral respiratory bandits.
Ann Allergy Asthma Immunol
September 2025
Arkansas Children's Research Institute, Little Rock, Arkansas; Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address:
Asthma affects approximately 25 million people in the United States, with respiratory viruses playing a significant role in both the onset and exacerbations of the condition. Although rhinovirus and respiratory syncytial virus (RSV) are the most well-known triggers, other iratory viruses playing a significant role in both the on, human parainfluenza virus, human bocavirus, enterovirus D68, influenza, and SARS-CoV-2 are increasingly recognized for their significant impact on asthma. These viruses contribute to both the development of asthma and exacerbations by inducing airway inflammation, disrupting epithelial barriers, and skewing immune responses-particularly toward type 2 inflammation.
View Article and Find Full Text PDFOn a wheeze and a prayer: The respiratory viral season.
Ann Allergy Asthma Immunol
September 2025
Division of Allergy and Immunology, Nationwide Children's Hospital - The Ohio State University College of Medicine, Columbus, Ohio. Electronic address:
Age-Dependent Risk of Bronchial Asthma Exacerbation in Respiratory Syncytial Virus Co-infection.
Lung
September 2025
Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Introduction: Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are common viral etiologies of respiratory infections. Although co-infection with other respiratory pathogens is frequently observed, its clinical significance remains unclear.
Methods: We retrospectively analyzed 57,746 patients who underwent FILMARRAY®, a comprehensive multiplex polymerase chain reaction testing, between November 2020 and March 2023.